Physician profile
Keith W Berkowitz
NPI 1174532113
$2,688.44
in general payments reported to CMS, 2019-2025
22 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $317 · 2021: $385 · 2022: $460 · 2023: $424 · 2024: $498 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $773.01 | 2019-2025 | Synthroid, Creon, Linzess |
| Ibsa Pharma INC. | $376.01 | 2019-2024 | Tirosint, Licart, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $361.52 | 2019-2024 | Xifaxan, Trulance |
| Novo Nordisk INC | $227.36 | 2019-2025 | Ozempic, Rybelsus |
| Acella Pharmaceuticals, LLC | $119.88 | 2023-2025 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $99.81 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $89.58 | 2024 | Breztri, Airsupra |
| Abbott Laboratories | $86.59 | 2023-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $84.73 | 2019-2024 | Zepbound, Mounjaro |
| Janssen Biotech, INC. | $69.98 | 2019 | |
| Exact Sciences Corporation | $65.09 | 2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $45.18 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $42.90 | 2023 | Adthyza |
| Avion Pharmaceuticals | $40.60 | 2023-2024 | NP Thyroid 60 |
| Janssen Pharmaceuticals, INC | $37.03 | 2024 | Spravato |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $35.14 | 2021 | |
| Dexcom, INC. | $34.55 | 2024 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $27.25 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $18.75 | 2019 | |
| Kaleo, INC. | $18.53 | 2022 | |
| Endo Pharmaceuticals INC. | $18.06 | 2019 | |
| Bausch Health US, LLC | $16.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Berkowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.